Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma

Michele Del Vecchio, Lorenza Di Guardo, Paolo A. Ascierto, Antonio M. Grimaldi, Vanna Chiarion Sileni, Jacopo Pigozzo, Virginia Ferraresi, Carmen Nuzzo, Gaetana Rinaldi, Alessandro Testori, Pier F. Ferrucci, Paolo Marchetti, Federica De Galitiis, Paola Queirolo, Elena Tornari, Riccardo Marconcini, Luana Calabrò, Michele Maio

Research output: Contribution to journalArticle

Abstract

Background Mucosal melanoma is an extremely rare and aggressive malignancy that often remains undetected until it reaches an advanced stage, when effective treatment options are limited. The activity and safety of ipilimumab were assessed in an Expanded Access Programme (EAP) that included patients with metastatic, mucosal melanoma. Methods Ipilimumab was available upon physician request for patients aged ≥16 years with stage III (unresectable) or IV skin, ocular or mucosal melanoma, who had failed or did not tolerate previous treatments and had no other therapeutic option available. Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. Patients with stable disease or an objective response to ipilimumab were eligible for retreatment upon disease progression. Tumour assessments were conducted at baseline and week 12 using immune-related response criteria. Patients were monitored for adverse events (AEs), including immune-related AEs, within 3 to 4 days of each scheduled visit. Results Of 855 patients participating in the EAP in Italy, 71 (8%) had metastatic, mucosal melanoma. With a median follow-up of 21.8 months, the response rate was 12% and the immune-related disease control rate was 36%. Median progression-free survival and overall survival were 4.3 and 6.4 months, respectively. In total, 34% of patients reported treatment-related AEs of any grade, which were grade 3 or 4 in 9% of patients. AEs were generally manageable as per protocol-specific guidelines. Conclusion/interpretation Ipilimumab may be a feasible treatment option in pretreated patients with metastatic mucosal melanoma, and warrants further investigation in prospective clinical trials.

Original languageEnglish
Pages (from-to)121-127
Number of pages7
JournalEuropean Journal of Cancer
Volume50
Issue number1
DOIs
Publication statusPublished - Jan 2014

Keywords

  • Efficacy
  • Expanded access programme
  • Ipilimumab
  • Metastatic melanoma
  • Mucosal
  • Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma'. Together they form a unique fingerprint.

  • Cite this